
Immunovant Inc (IMVT) Stock Forecast & Price Target
Immunovant Inc (IMVT) Analyst Ratings
Bulls say
Immunovant is a promising company with strong revenue potential due to its focused approach on developing IMVT-1402, a potential inhibitor of the FcRn receptor. Risks to its price target achievement include regulatory and clinical hurdles, the impact of COVID-19 on clinical development, and potential competition in the market. With the failure of its other drug in Phase 3 trials, the company is now fully dedicated to developing IMVT-1402 and has upcoming topline data from potentially registrational trials expected in 2027.
Bears say
Immunovant is in a strong position with their lead candidate IMVT-1402 showing robust response rates in highly refractory RA patients, with efficacy maintained in JAK-refractory patients. However, there are concerns regarding regulatory and clinical risks due to the potential cholesterol safety signal and the impact of COVID-19 on clinical development. Additionally, as a first-time product launch in a competitive market, there are financial risks with projected revenue not expected until 2027.
This aggregate rating is based on analysts' research of Immunovant Inc and is not a guaranteed prediction by Public.com or investment advice.
Immunovant Inc (IMVT) Analyst Forecast & Price Prediction
Start investing in Immunovant Inc (IMVT)
Order type
Buy in
Order amount
Est. shares
0 shares